IP and personalised medicine: a tailor-made approach

In 2017, the US Food and Drug Administration (FDA) approved a record 16 new personalised medicines, according to the “Personalized Medicine at FDA: 2017 Progress Report”. From 2014 to 2017, more than one in every four drugs the agency approved was a personalised medicine.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Medtech Magnolia fails to revive $2.1m verdict at Fed Circ

9 March 2026 Appeals court upholds lower court’s ruling, clarifying key legal questions concerning patent claims for blood‑testing devices.

Americas

Abbott IP chief: ‘Firms without AI policies scare me’

5 March 2026 The healthcare company’s chief IP counsel is researching how law firms and patent attorneys are using AI tools to inform its own guidelines for external legal providers.

Americas

Moderna inks billion-dollar deal to settle long-running Spikevax dispute

5 March 2026 Moderna settles, agreeing to part with up to $2.25 billion to avoid a trial and secure a licence to continue using the platform underpinning its COVID-19 vaccine.

More features

Medtech Magnolia fails to revive $2.1m verdict at Fed Circ

Nomination call: Influential Women in IP list closes ahead of International Women’s Day

Abbott IP chief: ‘Firms without AI policies scare me’

Moderna inks billion-dollar deal to settle long-running Spikevax dispute

DWT recruits first-chair trial litigator as latest hire in IP expansion

FisherBroyles opens San Diego office

To cite or not to cite: How can we avoid misuse of AI in court?

Emotional Perception: What next for patent holders?

IP and personalised medicine: a tailor-made approach

More on this story

Editor's picks

Editor's picks

More features